201014
N-苄基苯甲酰胺
≥98%
别名:
N-(苯基甲基)苯甲酰胺, N-苯甲酰苄胺, 苯甲酸苯甲酰胺
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
C6H5CONHCH2C6H5
化学文摘社编号:
分子量:
211.26
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
216-063-4
MDL number:
Assay:
≥98%
Quality Segment
assay
≥98%
mp
104-106 °C (lit.)
solubility
acetone: 25 mg/mL, clear, colorless
functional group
amide, phenyl
SMILES string
O=C(NCc1ccccc1)c2ccccc2
InChI
1S/C14H13NO/c16-14(13-9-5-2-6-10-13)15-11-12-7-3-1-4-8-12/h1-10H,11H2,(H,15,16)
InChI key
LKQUCICFTHBFAL-UHFFFAOYSA-N
General description
N-苄基苯甲酰胺抑制酪氨酸酶的活性。
Application
α 取代苄胺的便捷前体，用于滴定丁基锂和其他锂碱的指示剂。相关参考文献，请参见 Aldrichimica Acta 。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Manting Chiang et al.
Pharmaceutical research, 37(10), 205-205 (2020-09-30)
Modulation of 5-HT3 receptor in the central nervous system (CNS) is a promising approach for treatment of neuropathic pain. The goal was to evaluate the role of P-glycoprotein (Pgp) in limiting exposure of different parts of the CNS to ondansetron
Yae Eun Chong et al.
Biomedical chromatography : BMC, 33(11), e4653-e4653 (2019-07-20)
Ondansetron, a widely used antiemetic agent, is a P-glycoprotein (P-gp) substrate and therefore expression of P-gp at the blood-brain barrier limits its distribution to the central nervous system (CNS), which was observed to be reversed by coadministration with P-gp inhibitors.
Aldrichimica Acta, 11, 20-20 (1978)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 201014-5G | 04061831828825 |